NewAmsterdam Pharma (NAMS) Interest Expenses (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Interest Expenses data on file, last reported at $327.6 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 78.26% year-over-year to $327.6 million; the trailing twelve-month figure through Mar 2026 stood at $327.6 million (up 78.26% YoY), and the FY2025 full-year result was $442.9 million, up 48.63% from the prior year.
• Interest Expenses grew to $327.6 million in Q1 2026, from $1000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $327.6 million in Q1 2026 to a low of $1000.0 in Q4 2025.
• A 4-year average of $191.5 million and a median of $184.2 million in 2024 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 124.22% in 2025, while the deepest fall reached 100.0% in 2025.
• Tracing NAMS's Interest Expenses over 4 years: stood at $129.8 million in 2023, then surged by 42.24% to $184.6 million in 2024, then sank by 100.0% to $1000.0 in 2025, then surged by 32759400.0% to $327.6 million in 2026.
• Business Quant data shows NAMS's Interest Expenses at $327.6 million in Q1 2026, $1000.0 in Q4 2025, and $326.8 million in Q3 2025.